CD8A and neoplasm: reported that CD39+CD103+CD8+ TILs in the primary and metastatic sites of six malignant solid tumors had a unique TCR profile and killed autologous tumor cells effectively in an MHC-I-dependent manner in vitro, which demonstrated that this subpopulation was enriched in tumor-specific effector T cells.